Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

Vertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the cystic fibrosis drug Orkambi finally supplied to patients in England.

VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, ...

Sufferers now living an extra eight years on average following a Daily Express campaign to help people get lifesaving ...

Recent health news covers Vertex Pharmaceuticals' revenue uptick due to cystic fibrosis treatments, Britain's detection of ...

A Bicester School Sixth Form student "rediscovered her love of learning" earlier this year following a summer internship at ...

Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...

On Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX) maintained a positive stance from Oppenheimer, with a reiterated Outperform rating and a steady price target of $540.00.

(Reuters) - Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects ...

SCOTT, La., Oct. 31, 2024 /PRNewswire/ -- Gordon Technologies LLC ("Gordon"), an Enersol company, has acquired Vertex Downhole Trading LLC ("Vertex UAE"), which is the Eastern Hemisphere business ...